Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 17NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 59Sarcoma 34Dermatologic 9Thoracic 3Lymphoid 3Gynecologic 3Gastrointestinal 3Endocrine 3Breast 3Other solid neoplasm 2Other hematologic neoplasm 2Genitourinary 2

Conditions

Unspecified Childhood Solid Tumor, Protocol Specific 1Advanced Malignant Solid Neoplasm 1

Interventions

Cisplatin 28Irinotecan 18Gemcitabine 18Paclitaxel 14alvocidib 13Fluorouracil 11Oxaliplatin 10Cyclophosphamide 10Carboplatin 10Leucovorin 8Bortezomib 8Biopsy 8Taxes 7Radiotherapy 7Pemetrexed 7Magnetic Resonance Spectroscopy 7Doxorubicin 73-aminopyridine-2-carboxaldehyde thiosemicarbazone 7Specimen Handling 6tanespimycin 5Vorinostat 5LMB-100 5Early Intervention, Educational 5Bevacizumab 5temsirolimus 4sargramostim 4Sorafenib 4Sirolimus 4Platinum 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Temozolomide × Other solid neoplasm × Clear all
NCT01827384 2023-09-29

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

National Cancer Institute (NCI)

Phase 2 Completed
208 enrolled 27 charts
Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT01141244 2014-04-10

Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
72 enrolled
Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡